These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 14529503)

  • 1. The use of molecular descriptors in the design of gadolinium (III) chelates as MRI contrast agents.
    Maiocchi A
    Mini Rev Med Chem; 2003 Dec; 3(8):845-59. PubMed ID: 14529503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative structure-property relationship (correlation analysis) of phosphonic acid-based chelates in design of MRI contrast agent.
    Tiwari AK; Ojha H; Kaul A; Dutta A; Srivastava P; Shukla G; Srivastava R; Mishra AK
    Chem Biol Drug Des; 2009 Jul; 74(1):87-91. PubMed ID: 19519748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.
    Caravan P
    Acc Chem Res; 2009 Jul; 42(7):851-62. PubMed ID: 19222207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.
    Port M; Idée JM; Medina C; Robic C; Sabatou M; Corot C
    Biometals; 2008 Aug; 21(4):469-90. PubMed ID: 18344005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tris(pyrone) chelates of Gd(III) as high solubility MRI-CA.
    Puerta DT; Botta M; Jocher CJ; Werner EJ; Avedano S; Raymond KN; Cohen SM
    J Am Chem Soc; 2006 Feb; 128(7):2222-3. PubMed ID: 16478170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymeric gadolinium chelate magnetic resonance imaging contrast agents: design, synthesis, and properties.
    Ladd DL; Hollister R; Peng X; Wei D; Wu G; Delecki D; Snow RA; Toner JL; Kellar K; Eck J; Desai VC; Raymond G; Kinter LB; Desser TS; Rubin DL
    Bioconjug Chem; 1999; 10(3):361-70. PubMed ID: 10346865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance.
    Runge VM; Ai T; Hao D; Hu X
    Invest Radiol; 2011 Dec; 46(12):807-16. PubMed ID: 22094366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadolinium meets medicinal chemistry: MRI contrast agent development.
    Zhang Z; Nair SA; McMurry TJ
    Curr Med Chem; 2005; 12(7):751-78. PubMed ID: 15853710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cleavable β-cyclodextrin nanocapsules incorporating Gd(III)-chelates as bioresponsive MRI probes.
    Martinelli J; Fekete M; Tei L; Botta M
    Chem Commun (Camb); 2011 Mar; 47(11):3144-6. PubMed ID: 21270985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Stability" of gadolinium chelates.
    Tweedle MF
    Br J Radiol; 2007 Jul; 80(955):583-4; author reply 584-5. PubMed ID: 17704319
    [No Abstract]   [Full Text] [Related]  

  • 11. New aromatic macrocyclic gadolinium chelates with enhanced relaxivity.
    Zhang X; Pillai R; Shukla R; Ranganathan RS; Tweedle M
    Invest Radiol; 1994 Jun; 29 Suppl 2():S69-70. PubMed ID: 7928275
    [No Abstract]   [Full Text] [Related]  

  • 12. Stability of linear and macrocyclic gadolinium based contrast agents.
    Schmitt-Willich H
    Br J Radiol; 2007 Jul; 80(955):581-2; author reply 584-5. PubMed ID: 17704318
    [No Abstract]   [Full Text] [Related]  

  • 13. QSPR prediction of the stability constants of gadolinium(III) complexes for magnetic resonance imaging.
    Dioury F; Duprat A; Dreyfus G; Ferroud C; Cossy J
    J Chem Inf Model; 2014 Oct; 54(10):2718-31. PubMed ID: 25181704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARACEST agents: modulating MRI contrast via water proton exchange.
    Zhang S; Merritt M; Woessner DE; Lenkinski RE; Sherry AD
    Acc Chem Res; 2003 Oct; 36(10):783-90. PubMed ID: 14567712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bifunctional Gd(III) and Tb(III) chelates based on a pyridine-bis(iminodiacetate) platform, suitable optical probes and contrast agents for magnetic resonance imaging.
    Laurent S; Vander Elst L; Galaup C; Leygue N; Boutry S; Picard C; Muller RN
    Contrast Media Mol Imaging; 2014; 9(4):300-12. PubMed ID: 24706614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging.
    Werner EJ; Datta A; Jocher CJ; Raymond KN
    Angew Chem Int Ed Engl; 2008; 47(45):8568-80. PubMed ID: 18825758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadolinium-binding helix-turn-helix peptides: DNA-dependent MRI contrast agents.
    Caravan P; Greenwood JM; Welch JT; Franklin SJ
    Chem Commun (Camb); 2003 Oct; (20):2574-5. PubMed ID: 14594287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A DNA-binding Gd chelate for the detection of cell death by MRI.
    Garanger E; Hilderbrand SA; Blois JT; Sosnovik DE; Weissleder R; Josephson L
    Chem Commun (Camb); 2009 Aug; (29):4444-6. PubMed ID: 19597620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An MRI contrast agent based on a zwitterionic metal-chelating polymer for hepatorenal angiography and tumor imaging.
    Zhang P; Wang Z; Wang Y; Wang Y; Liu C; Cao K; Lu Y; Behboodpour L; Hou Y; Gao M
    J Mater Chem B; 2020 Aug; 8(31):6956-6963. PubMed ID: 32490870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AAZTA-based bifunctional chelating agents for the synthesis of multimeric/dendrimeric MRI contrast agents.
    Gugliotta G; Botta M; Tei L
    Org Biomol Chem; 2010 Oct; 8(20):4569-74. PubMed ID: 20740241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.